Von der Leyen’s AI Vision Relies on Foreign Tech for European Values

The strategy shifts away from competing with American or Chinese labs to develop frontier models, acknowledging that Europe’s current champion, Mistral, remains dependent on US-based Anthropic. Instead of chasing technical parity, von der Leyen proposes leveraging the bloc's regulatory weight alongside partners like the UK and Canada. The goal is to steer technology toward tangible benefits in the real economy, specifically within healthcare and industrial settings.

Highlighting breast cancer screening as a primary use case, she argued that artificial intelligence should augment medical expertise rather than replace it. She insisted that human agency must remain central to the digital transition, characterizing this control as the defining feature of the European way. Yet, this vision creates a notable tension: while promoting autonomy, the EU’s domestic policy ambitions remain fundamentally tethered to the infrastructure provided by private, foreign-owned corporations.